Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Hematologic Neoplasms
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids

abstract

  • These results suggest that SAHA has activity in hematologic malignancies including HD and select subtypes of non-Hodgkin's lymphoma.

publication date

  • January 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.01.9679

PubMed ID

  • 16330674

Additional Document Info

start page

  • 166

end page

  • 73

volume

  • 24

number

  • 1